Related content

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia

By  

CANCER, Vol. 120, Iss. 10, 2014-05 ,pp. : 1514-1519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough

By  

Case Reports in Oncology, Vol. 4, Iss. 2, 2011-06 ,pp. : 323-326

Karger

Access to resources Recommend Favorite

Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 2941-2951

John Wiley & Sons Inc

Access to resources Recommend Favorite

BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 248-254

Karger

Access to resources Recommend Favorite